8-K: Kairos Pharma Secures $3.5 Million in Private Placement, Issues Warrants

Kairos Pharma, Ltd. has entered into a securities purchase agreement to raise $3.5 million through the sale of common and pre-funded units, including warrants.

Summary

• Kairos Pharma, Ltd. has secured a $3.5 million private placement through a securities purchase agreement.
• The offering includes the sale of common units at $1.40 each and pre-funded units at $1.399 each.
• Each common unit consists of one common share and a warrant to purchase 1.5 common shares.
• Each pre-funded unit includes a pre-funded warrant to purchase one common share and a warrant to purchase 1.5 common shares.
• The pre-funded warrants have an exercise price of $0.001 per share and are immediately exercisable.
• The common warrants have an exercise price of $1.40 per share, are exercisable six months from issuance, and expire five and a half years from the issuance date.
• Investors are subject to beneficial ownership limitations of 4.99% or 9.99%, which can be increased with 61 days prior notice.
• The final closing of the offering is expected to occur on or about January 15, 2025.
• The company has also entered into a registration rights agreement requiring the filing of a registration statement for the resale of the shares and warrant shares.
• Executive officers, directors, and major stockholders have agreed to a 90-day lock-up period.

Sentiment

Score: 7

Explanation: The document indicates a successful capital raise, which is generally positive. However, the potential for dilution from warrants and the lock-up period introduce some uncertainty.

Positives

• The company has successfully raised $3.5 million in capital.
• The pre-funded warrants provide immediate access to capital for the company.
• The offering includes warrants which could provide additional capital in the future.
• The lock-up agreement provides stability for the company's stock price in the short term.
• The registration rights agreement provides liquidity for investors.

Negatives

• The offering includes warrants which could dilute the stock in the future.
• The beneficial ownership limitations may restrict some investors.
• The lock-up agreement may limit the ability of key personnel to sell their shares in the short term.

Risks

• The exercise of warrants could dilute the existing shares.
• The company's stock price could be affected by the sale of shares by investors after the lock-up period.
• The company may not be able to meet the deadlines for filing the registration statement.
• The company may not be able to maintain the listing of its common stock on the NYSE American.

Future Outlook

The company expects to close the offering on or about January 15, 2025, and will file a registration statement for the resale of the securities. The company intends to use the proceeds for working capital purposes.

Management Comments

• The company has not provided any direct quotes from management in this document.

Industry Context

Private placements are a common method for companies, especially those in the biotech sector, to raise capital. The use of warrants is also a common practice to attract investors. The lock-up agreement is a standard measure to prevent a sudden drop in the stock price after the offering.

Comparison to Industry Standards

• The terms of the warrants, including the exercise price and expiration date, are fairly standard for private placements in the biotech industry.
• The beneficial ownership limitations are also common to prevent any single investor from gaining too much control.
• The 90-day lock-up period is a typical duration for such agreements.
• Comparable companies in the biotech sector often use similar financing methods, including private placements with warrants, to fund their operations and research.
• The use of a registration rights agreement is also a standard practice to provide liquidity to investors.

Stakeholder Impact

• Shareholders may experience dilution from the issuance of new shares and warrants.
• Employees may be affected by the lock-up agreement if they hold shares or options.
• Investors will have the opportunity to resell their shares after the registration statement becomes effective.
• The company will have additional capital to fund its operations.

Next Steps

• The company will close the offering on or about January 15, 2025.
• The company will file a registration statement within 15 days of the closing.
• The company will seek to list the shares and warrant shares on the NYSE American.

Key Dates

Keywords

private placement, warrants, common stock, pre-funded warrants, registration rights, lock-up agreement, capital raise, securities purchase agreement, beneficial ownership, Kairos Pharma